PuMP: Oncolytic HSV1 MVR-C5252 in Patients with rHGG (Recurrent Glioma)

What is the Purpose of this Study?

We are doing this study to find out how safe and effective an experimental drug called MVR-C5252 (the study drug) is for people with advanced brain cancer.

What is the Condition Being Studied?

Malignant Glioma

Who Can Participate in the Study?

Adults ages 18+ who are diagnosed with recurrent high-grade glioma.

For more information about this study, please call 919-668-3726.

Age Group
Adults

What is Involved?

If you join the study, you will:

  • Have a physical and neurological exam and other tests
  • Have magnetic resonance imaging (MRI) of the brain
  • Have blood draws
  • Have brain tumor biopsy and testing of tumor sample
  • Have a catheter (small flexible tube) placed in and around the tumor with the other end of the catheter extending slightly outside of the head
  • Get the study drug infused through an external pump and the implanted catheter

Study Details

Full Title
The PuMP Trial: A Multistage Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 in Patients with Recurrent High-Grade Glioma
Principal Investigator
Headshot of Mustafa Khasraw
Professor of Neurosurgery
Protocol Number
IRB: PRO00112883
NCT: NCT06126744
Phase
Phase I
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL
Participate